MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
0.4930
+0.0030
+0.61%
After Hours: 0.4930 0 0.00% 16:10 09/30 EDT
OPEN
0.4893
PREV CLOSE
0.4900
HIGH
0.5100
LOW
0.4769
VOLUME
59.99K
TURNOVER
--
52 WEEK HIGH
2.060
52 WEEK LOW
0.2810
MARKET CAP
16.47M
P/E (TTM)
-0.3327
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTA last week (0921-0925)?
Weekly Report · 2d ago
H.C. Wainwright Sticks to Its Buy Rating for Pasithea Therapeutics Corp (KTTA)
TipRanks · 09/22 09:45
Weekly Report: what happened at KTTA last week (0914-0918)?
Weekly Report · 09/21 09:21
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 09/18 21:06
Pasithea Therapeutics Announces Nasdaq Warrant Expiration
TipRanks · 09/16 20:31
Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results
Benzinga · 09/14 11:08
Weekly Report: what happened at KTTA last week (0907-0911)?
Weekly Report · 09/14 09:22
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Barchart · 09/14 06:00
More
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.